AstraZeneca overhauls management of its China division, FT reports

(Reuters) - AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct knowledge of the matter.

The Anglo-Swedish drugmaker has promoted Mary Guan to lead oncology in China, according to the report.

AstraZeneca did not immediately respond to a Reuters request for comment.

Last month, the company named Iskra Reic as its new international executive vice president, taking over from Leon Wang, who was detained by Chinese authorities in October.

AstraZeneca said in November that in addition to the Chinese authorities' investigation into Wang, the company is also aware of two separate and ongoing probes by the Chinese government into its activities in the country. One involves suspected medical insurance fraud, and the other relates to the importation of cancer drugs from Hong Kong into mainland China.

(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Shounak Dasgupta)